SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Lockdown leads to double unplanned pregnancies
Fri October 22nd - Unplanned pregnancies almost doubled during the first lockdown in the UK, a major study reports today. More
Promising development in treatment for glioblastoma multiforme
Fri October 22nd - A major advance in brain tumour research could pave the way for personalised treatment for the most deadly form of the disease, British scientists say. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Cancer treatment hope from Oxford COVID vaccine technology

Friday September 3rd 2021

The technology behind the Oxford-AstraZeneca COVID-19 vaccine could be used to help treat cancer, it is revealed today.

Research from the University of Oxford and the Ludwig Institute for Cancer Research has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, when combined with immunotherapy, decreases tumour size and increases survival rates in mouse models.

Thanks to this finding, which is published in the Journal for ImmunoTherapy of Cancer, a phase 1/2a clinical trial in 80 patients with non-small cell lung cancer will start later this year.

The study, which was carried out by Professor Benoit Van den Eynde’s group at the Ludwig Institute for Cancer Research, University of Oxford, with co-authors Professor Adrian Hill and Dr Irina Redchenko at the University’s Jenner Institute, follows the discovery that Oxford’s COVID-19 vaccine technology generates strong CD8+ T cell responses.

The team developed a two-dose therapeutic cancer vaccine with different prime and boost viral vectors and to create a vaccine treatment that specifically targets cancer cells, the vaccine was designed to target MAGE-A3 and NY-ESO-1 proteins that are present on the surface of many types of cancer cells.

In preclinical experiments in mouse tumour models, the cancer vaccine increased the levels of tumour-infiltrating CD8+ T cells and enhanced the response to anti-PD-1 immunotherapy.

The combined vaccine and anti-PD-1 treatment resulted in a greater reduction in tumour size and improved the survival of the mice compared to anti-PD-1 therapy alone.

Professor Benoit Van den Eynde, professor of tumour immunology at the University of Oxford said: “We knew from our previous research that MAGE-type proteins act like red flags on the surface of cancer cells to attract immune cells that destroy tumours.

“MAGE proteins have an advantage over other cancer antigens as vaccine targets since they are present on a wide range of tumour types. This broadens the potential benefit of this approach to people with many different types of cancer.

“Importantly for target specificity, MAGE-type antigens are not present on the surface of normal tissues, which reduces the risk of side-effects caused by the immune system attacking healthy cells.”

Adrian Hill, Lakshmi Mittal and Family professorship of vaccinology and director of the Jenner Institute, University of Oxford, said the new vaccine platform has the potential to revolutionise cancer treatment.

“The forthcoming trial in non-small cell lung cancer follows a Phase 2a trial of a similar cancer vaccine in prostate cancer undertaken by the University of Oxford that is showing promising results,” he said.

“Our cancer vaccines elicit strong CD8+ T cell responses that infiltrate tumours and show great potential in enhancing the efficacy of immune checkpoint blockade therapy and improving outcomes for patients with cancer.”

Journal for ImmunoTherapy of Cancer 3 September 2021

Tags: Cancer | Flu & Viruses | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES